US FDA’s Streamlined Drug Approval Packages Shine Less Light On Sponsor Interactions

CDER is no longer proactively posting mid- and late-cycle meeting minutes and certain correspondence with sponsors for new drug and biologic approvals; drugs center says it is focused on ensuring the most scientifically meaningful information is prioritized and posted in a timely manner, but some observers say the change raises transparency concerns.

hand open curtain - concept of change and reveal new better world
FDA's drugs center is not pulling back the curtain on new drugs reviews quite as much as it used to.

The US FDA’s Center for Drug Evaluation and Research (CDER) is proactively releasing less information about the drugs and biologics it approves in the name of faster disclosure of the most important details about its reviews.

The drugs center has stopped posting to its website certain correspondence and minutes of meetings with sponsors about approved new...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Product Reviews

More from Pink Sheet

Adaptive Clinical Trials Require ‘Clear And Compelling Justification’

 
• By 

A draft international guideline on using adaptive trial designs says sponsors should provide a clear rationale for using such designs to address the potential ‘tension’ between the confirmatory nature of late-stage trials and the flexibility introduced by mid-trial adaptations.

What Pharma Needs To Know About Vietnam’s Drug Registration Reforms

 

Newly introduced rules for streamlining drug registration in Vietnam are said to present both opportunities and challenges for stakeholders.

European Industry Calls For Support As It Juggles Multiple Challenges

 
• By 

At Medicines for Europe’s legal and annual conferences in Brussels last week, multiple key issues competed for attention, giving the generics and biosimilars industry plenty to think about at a critical time for EU pharma reform.